Independent minds. Global perspective. A publication for the builders
Biotechnology / Salt Lake City, UT

Rachel Garlick.

Co-founder
Eris Biotech

Rachel Garlick is a founder of Eris Biotech, which researches small molecule cancer therapies. She holds an immunology doctorate from Dartmouth and previously worked on cell therapies. Her co-founder relationship began through a shared academic laboratory, where they collaborated on research before following different paths in drug development.

Public-source researchLast checked 1 source ↘
THE STORY, IN CONTEXT

Rachel Garlick and the story of Eris Biotech.

Eris' founders connect the venture to concerns they encountered about treatment toxicity and immune suppression. Their current research begins with mesothelioma and investigates a mechanism associated with tumour immune evasion. Garlick's immunology and cell therapy background supplies relevant professional context. The source describes a development thesis; statements about avoiding side effects or eliminating cancer are not established clinical outcomes and are not adopted as facts in this profile.

FROM THE PUBLIC RECORD

Public advice & further reading.

No personal advice is attributed in this profile: a verifiable public advice source has not yet been established. The company and activity facts above remain separately sourced.

Suggest a first-person interview or essay ↗
EVIDENCE IN PLAIN SIGHT

Sources & attribution.

  1. 01
    Eris Biotech — Y Combinator company and active founder profile

    Public active-founder biography, current company status and description, and founding-team launch accounts. Company or team statements are attributed accounts, not independently audited performance results.

    www.ycombinator.com
About this profile

Independently researched from the public sources above. Featured people and companies are not affiliated with BusinessBlogz. Source dates and attribution provide context for the information shown; business claims remain attributed to their original source. Role and company details can change after review. The initials graphic is editorial artwork, not a photograph.

Request a correction or update ↗
KEEP EXPLORING

More builders in Biotechnology.

Explore the sector ↗